Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

John B.A.G. Haanen(The Netherlands Cancer Institute), Franck Carbonnel, Caroline Robert(Institut Gustave Roussy), Keith M. Kerr, Solange Peters(University Hospital of Lausanne), James Larkin(Royal Marsden Hospital), Karin Jordan(University Hospital Heidelberg)

Annals of Oncology

May 5, 2017

10.1093/annonc/mdx225

Cited by 2,342

Abstract

Related Papers

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al.|New England Journal of Medicine|2010|15.1k

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al.|New England Journal of Medicine|2015|9.4k

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al.|New England Journal of Medicine|2015|6.2k

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al.|The Lancet|2014|1.8k

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al.|The Lancet Oncology|2015|1.6k